drugset / Trial / NCT02559830

Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy

NCT02559830 ↗

NaSingle-groupOpen-labelTreatment

Summary

Evaluating the safety and efficacy of Lentiviral Hematopoietic Stem Cell Gene Therapy for advanced stage of Metachromatic Leukodystrophy and adrenoleukodystrophy.

Timeline

Start
2015-01
Primary completion
2025-10
Completion
2025-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject transduced CD34+ hematopoietic stem cell Unknown 2 cells/kg —
Subject transduced CD34+ hematopoietic stem cell Unknown 20 cells/kg —